- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- NAG-NAG-NAG.23: 4 residues within 4Å:- Chain D: N.73, S.75, I.76, Y.80
 No protein-ligand interaction detected (PLIP)- NAG-NAG-NAG.24: 4 residues within 4Å:- Chain F: N.73, S.75, I.76, Y.80
 No protein-ligand interaction detected (PLIP)- NAG-NAG-NAG.25: 4 residues within 4Å:- Chain H: N.73, S.75, I.76, Y.80
 No protein-ligand interaction detected (PLIP)
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
- NAG.26: 2 residues within 4Å:- Chain A: Y.28, N.61
 Ligand excluded by PLIP- NAG.27: 3 residues within 4Å:- Chain A: N.122, T.124, V.127
 Ligand excluded by PLIP- NAG.28: 2 residues within 4Å:- Chain A: E.132, N.165
 Ligand excluded by PLIP- NAG.29: 2 residues within 4Å:- Chain A: G.232, N.234
 Ligand excluded by PLIP- NAG.30: 3 residues within 4Å:- Chain A: N.280, E.281, N.282
 Ligand excluded by PLIP- NAG.31: 2 residues within 4Å:- Chain A: N.603, T.604
 Ligand excluded by PLIP- NAG.32: 1 residues within 4Å:- Chain A: N.616
 Ligand excluded by PLIP- NAG.33: 1 residues within 4Å:- Chain A: N.657
 Ligand excluded by PLIP- NAG.34: 4 residues within 4Å:- Chain A: N.709, I.1130, G.1131
- Chain B: D.796
 Ligand excluded by PLIP- NAG.35: 1 residues within 4Å:- Chain B: N.61
 Ligand excluded by PLIP- NAG.36: 3 residues within 4Å:- Chain B: N.122, V.127, K.129
 Ligand excluded by PLIP- NAG.37: 1 residues within 4Å:- Chain B: N.165
 Ligand excluded by PLIP- NAG.38: 2 residues within 4Å:- Chain A: H.519
- Chain B: N.234
 Ligand excluded by PLIP- NAG.39: 3 residues within 4Å:- Chain A: K.558
- Chain B: E.281, N.282
 Ligand excluded by PLIP- NAG.40: 1 residues within 4Å:- Chain B: N.603
 Ligand excluded by PLIP- NAG.41: 1 residues within 4Å:- Chain B: N.616
 Ligand excluded by PLIP- NAG.42: 1 residues within 4Å:- Chain B: N.657
 Ligand excluded by PLIP- NAG.43: 5 residues within 4Å:- Chain B: A.706, E.1072, K.1073, N.1074
- Ligands: NAG.44
 Ligand excluded by PLIP- NAG.44: 1 residues within 4Å:- Ligands: NAG.43
 Ligand excluded by PLIP- NAG.45: 2 residues within 4Å:- Chain C: Y.28, N.61
 Ligand excluded by PLIP- NAG.46: 1 residues within 4Å:- Chain C: N.122
 Ligand excluded by PLIP- NAG.47: 3 residues within 4Å:- Chain B: R.357, Y.396
- Chain C: N.165
 Ligand excluded by PLIP- NAG.48: 1 residues within 4Å:- Chain C: N.234
 Ligand excluded by PLIP- NAG.49: 3 residues within 4Å:- Chain C: N.280, E.281, N.282
 Ligand excluded by PLIP- NAG.50: 1 residues within 4Å:- Chain C: N.603
 Ligand excluded by PLIP- NAG.51: 1 residues within 4Å:- Chain C: N.616
 Ligand excluded by PLIP- NAG.52: 1 residues within 4Å:- Chain C: N.657
 Ligand excluded by PLIP
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. (2021)
            
- Release Date
- 2021-03-10
- Peptides
- Spike glycoprotein: ABC
 Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214: DFH
 IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant: EGI
- SMTL:PDB
- SMTL Chain Id:
 PDB Chain Id:A
 AB
 BC
 CD
 HF
 IH
 JE
 KG
 MI
 N
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. (2021)
            
- Release Date
- 2021-03-10
- Peptides
- Spike glycoprotein: ABC
 Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214: DFH
 IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant: EGI
- SMTL:PDB
- SMTL Chain Id:
 PDB Chain Id:A
 AB
 BC
 CD
 HF
 IH
 JE
 KG
 MI
 N